Teva Pharmaceutical Industries Ltd (Teva) (TASE:TEVA) (HYSE:TEVA) announced on Monday the launch of a generic version of VESIcare 1 (solifenacin succinate) tablets, 5 mg and 10 mg, in the US.

Solifenacin succinate tablets are a muscarinic antagonist indicated for the treatment of overactive bladder with symptoms of urge urinary incontinence, urgency and urinary frequency. Overactive bladder (OAB) is most often characterised by a strong sudden urge to urinate that is difficult to control.

Reportedly, VESIcare tablets had annual sales of over USD955m in the US, according to IQVIA data as of February 2019.

According to Teva, with nearly 500 generic medicines available, it has the largest portfolio of FDA-approved generic products on the market and holds the leading position in first-to-file opportunities, with over 100 pending first-to-files in the US. Currently, one in eight generic prescriptions dispensed in the US is filled with a Teva generic product.

Teva Pharmaceutical Industries is a leader in generic and specialty medicines with a portfolio consisting of over 35,000 products in nearly every therapeutic area.